Alastair Garfield - 01 Jul 2026 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Reporting relationship: Chief Scientific Officer
Issuer ticker: RYTM
Reported as of: 01 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Jul 2026, 16:52:49 UTC
Prior SEC filing: 13 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Stephen Vander Stoep, attorney-in-fact for Alastair Garfield

Key filing fact

Alastair Garfield filed Form 4 for RHYTHM PHARMACEUTICALS, INC. (RYTM) on 02 Jul 2026.

Key facts

This page summarizes Alastair Garfield's Form 4 filing for RHYTHM PHARMACEUTICALS, INC. (RYTM).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 02 Jul 2026, 16:52.

Change

Previous filing in this sequence was filed on 13 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002027261 Primary reporting owner

Garfield Alastair

Relationship: Chief Scientific Officer
Address: 222 BERKELEY STREET, 12TH FLOOR, BOSTON
Signature: /s/ Stephen Vander Stoep, attorney-in-fact for Alastair Garfield
Signature date: 02 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RYTM transaction

Common Stock

Options Exercise

Transaction value
Shares: +4,445
Change %: +57%
Price
Shares after: 12,208
Date: 01 Jul 2026
Ownership: Direct
Footnotes: F1

RYTM transaction

Common Stock

Tax liability

Transaction value
Shares: -2,150
Change %: -18%
Price: $110.41^*
Shares after: 10,058
Date: 01 Jul 2026
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RYTM transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -4,445
Change %: -33%
Price: $0.000000^*
Shares after: 8,888
Date: 01 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 4,445
Exercise price
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

Footnote F2

These shares were withheld for payment of the withholding taxes upon the vesting of the restricted stock units reported herein.

Footnote F3

The restricted stock units vest as to 25% of the total restricted stock units on each of the first four anniversaries of July 1, 2024, subject to the Reporting Person's continued service on each such vesting date. The restricted stock units have no expiration date.